| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg | |||
| Other Sizes |
| Targets |
nACh receptor; Norepinephrine uptake ( IC50 = 1.7 μM )
Hydroxybupropion targets the same transporters as its parent drug, Bupropion. Bupropion is an atypical antidepressant of the aminoketone group, structurally related to cathinone. It inhibits the reuptake of dopamine and norepinephrine, and its metabolite Hydroxybupropion contributes to its overall pharmacological activity. Hydroxybupropion exhibits greater anti-bupropion activity (indicating antidepressant activity in animals). |
|---|---|
| ln Vitro |
In vitro, Hydroxybupropion is characterized as a major active metabolite of Bupropion. It exhibits greater anti-bupropion activity (indicating antidepressant activity in animals) and has pharmacological activity than erythro- and threo-hydroxybupropion. It antagonizes nicotine.
|
| ln Vivo |
The concentration of hydroxybupropion greatly exceeds the concentration of the parent drug, reaching 10 to 100 times the concentration of bupropion. Hydroxybupropion exhibits greater anti-bupropion activity (indicating antidepressant activity in animals) and has pharmacological activity than erythro- and threo-hydroxybupropion, inhibiting solutions of norbenazol and dopamine, Antagonizes nicotine and exhibits antidepressant effects in rodents [1].
In vivo, Hydroxybupropion contributes to the antidepressant effects of Bupropion in animal models. It exhibits antidepressant effects in rodents and antagonizes nicotine. As a major metabolite, it is formed in vivo following Bupropion administration and contributes to the overall therapeutic effect of the parent drug. |
| Enzyme Assay |
In vitro assays for Hydroxybupropion typically involve measuring its effects on neurotransmitter transporters. Cells expressing dopamine or norepinephrine transporters are treated with increasing concentrations of the compound, and neurotransmitter uptake is measured using radiolabeled substrates. IC50 values are calculated from dose-response curves. The compound's activity is compared to Bupropion and other metabolites.
|
| Cell Assay |
For in vitro cell-based assays, cells expressing neurotransmitter transporters are cultured and treated with Hydroxybupropion at various concentrations. Transporter inhibition is confirmed by measuring the uptake of radiolabeled dopamine or norepinephrine. Cell viability is assessed by standard assays. The compound's effects on downstream signaling pathways are analyzed by Western blot or other appropriate methods.
|
| Animal Protocol |
In vivo animal studies with Hydroxybupropion are conducted in models of depression and nicotine addiction. The compound is administered orally or intraperitoneally to rodents. Antidepressant-like effects are assessed using behavioral tests such as the forced swim test or tail suspension test. Nicotine antagonism is assessed by measuring nicotine-induced behaviors. The compound's antidepressant effects in rodents have been demonstrated.
|
| ADME/Pharmacokinetics |
Hydroxybupropion (CAS: 92264-81-8) has a molecular weight of 255.74 g/mol and a molecular formula of C13H18ClNO2. IUPAC name: 1-(3-chlorophenyl)-2-[(1-hydroxy-2-methylpropan-2-yl)amino]propan-1-one. Appearance: solid powder. Purity: ≥98%. Storage: -20°C. The compound is a major active metabolite of Bupropion.
|
| Toxicity/Toxicokinetics |
Hydroxybupropion is a research compound and is not approved for human therapeutic use as a standalone drug. As a metabolite of Bupropion, it shares the toxicity profile of the parent drug. Bupropion is generally well-tolerated, with common side effects including insomnia, dry mouth, and seizures at high doses. Standard laboratory safety precautions should be followed when handling the compound.
|
| References | |
| Additional Infomation |
Hydroxybutyric acid acetone is an aromatic ketone.
Hydroxybupropion is a major active metabolite of Bupropion, a marketed antidepressant and smoking cessation drug. It exhibits greater antidepressant activity than other bupropion metabolites and antagonizes nicotine. It has a molecular weight of 255.74 g/mol and a molecular formula of C13H18ClNO2. It is not FDA-approved as a standalone drug and is intended for research use only. |
| Molecular Formula |
C₁₃H₁₈CLNO₂
|
|---|---|
| Molecular Weight |
255.74
|
| Exact Mass |
255.103
|
| CAS # |
92264-81-8
|
| Related CAS # |
Bupropion morpholinol; 357399-43-0; Bupropion morpholinol-d6; 1216893-18-3; Radafaxine; 192374-14-4
|
| PubChem CID |
446
|
| Appearance |
White to off-white solid
|
| Density |
1.15 g/cm3
|
| Boiling Point |
393.9ºC at 760 mmHg
|
| Melting Point |
121-123ºC
|
| Flash Point |
192ºC
|
| LogP |
2.662
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
17
|
| Complexity |
268
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(C(C)NC(CO)(C)C)C1C=C(Cl)C=CC=1
|
| InChi Key |
AKOAEVOSDHIVFX-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C13H18ClNO2/c1-9(15-13(2,3)8-16)12(17)10-5-4-6-11(14)7-10/h4-7,9,15-16H,8H2,1-3H3
|
| Chemical Name |
1-(3-chlorophenyl)-2-[(1-hydroxy-2-methylpropan-2-yl)amino]propan-1-one
|
| Synonyms |
Hydroxybupropion
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~391.0 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (9.78 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (9.78 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (9.78 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.9102 mL | 19.5511 mL | 39.1022 mL | |
| 5 mM | 0.7820 mL | 3.9102 mL | 7.8204 mL | |
| 10 mM | 0.3910 mL | 1.9551 mL | 3.9102 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
